AZ's Dapagliflozin Impresses In Topline Phase III Heart Failure Study

20 Aug 2019

• By John Davis

AstraZeneca’s SGLT2 inhibitor has grabbed attention for its potential role in chronic heart failure patients, with or without type 2 diabetes, following initial results from the DAPA-HF study.

AstraZeneca PLC’s Farxiga/Forxiga (dapagliflozin) has become the first SGLT2 inhibitor to show a reduction in the risk of cardiovascular death or worsening of heart failure in patients with reduced ejection fraction heart failure (HFrEF), with or without type 2 diabetes, when added to the standard of care.

The positive results, from the DAPA-HF study, should give a boost to dapagliflozin, whose sales grew by 14% to reach $737m in the first half of 2019

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

Pipeline Watch: Thirteen Approvals And Ten Phase III Readouts

06 May 2025

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Accelerated Approval May Be Out Of Reach For PTC’s Huntington’s Drug

05 May 2025

• By Joseph Haas

PTC said its updated Phase II data for PTC 518 met the primary endpoint of Huntingtin’s protein reduction, but analysts said there isn’t clear correlation with clinical benefit.